Imagion Biosystems has today released its Appendix 4C Quarterly Cashflow report and update on company activities for the quarter ending 31 March 2020.
Read the Quarterly Cashflow Report.
Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review
June 3, 2026
Imagion Biosystems, Ltd. (ASX: IBX) has announced that the US Food and Drug Administration (FDA) completed its review of the company’s investigational new drug (IND)